AIM ImmunoTech, Inc. (AIM)
0.1626
-0.01
(-4.35%)
USD |
NYAM |
Oct 22, 16:00
0.1626
0.00 (0.00%)
After-Hours: 16:25
AIM ImmunoTech Enterprise Value : -1.115M for Oct. 21, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 21, 2026 | -1.115M |
| October 20, 2026 | -1.225M |
| October 19, 2026 | -1.315M |
| October 16, 2026 | -1.170M |
| October 15, 2026 | -1.106M |
| October 14, 2026 | -1.352M |
| October 13, 2026 | -1.118M |
| October 12, 2026 | -0.9002M |
| October 09, 2026 | -0.8248M |
| October 08, 2026 | -0.8364M |
| October 07, 2026 | -0.7436M |
| October 06, 2026 | -0.7523M |
| October 05, 2026 | -0.5349M |
| October 02, 2026 | -0.8248M |
| October 01, 2026 | -0.6016M |
| September 30, 2026 | -0.9697M |
| September 29, 2026 | -1.013M |
| September 28, 2026 | -0.6972M |
| September 25, 2026 | -0.532M |
| September 24, 2026 | -0.1493M |
| September 23, 2026 | 0.0449M |
| September 22, 2026 | 0.2073M |
| September 21, 2026 | 0.0304M |
| September 18, 2026 | -0.0276M |
| September 17, 2026 | 0.2565M |
| Date | Value |
|---|---|
| September 16, 2026 | 0.1029M |
| September 15, 2026 | 0.1493M |
| September 14, 2026 | 0.4189M |
| September 11, 2026 | 0.3841M |
| September 10, 2026 | 0.5349M |
| September 09, 2026 | 0.7175M |
| September 08, 2026 | 0.616M |
| September 04, 2026 | 0.5551M |
| September 03, 2026 | 0.732M |
| September 02, 2026 | 0.7581M |
| September 01, 2026 | 0.7987M |
| August 31, 2026 | 0.5088M |
| August 28, 2026 | 1.448M |
| August 27, 2026 | 1.204M |
| August 26, 2026 | 1.204M |
| August 25, 2026 | 1.320M |
| August 24, 2026 | 1.320M |
| August 21, 2026 | 1.448M |
| August 20, 2026 | 1.294M |
| August 19, 2026 | 0.8624M |
| August 18, 2026 | 0.7378M |
| August 17, 2026 | 1.002M |
| August 14, 2026 | 0.3319M |
| August 13, 2026 | 1.454M |
| August 12, 2026 | 1.408M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.593B |
| Alnylam Pharmaceuticals, Inc. | 29.78B |
| Anika Therapeutics, Inc. | 262.53M |
| Savara, Inc. | 816.59M |
| Vericel Corp. | 2.027B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.788M |
| Revenue (Quarterly) | 0.026M |
| Total Expenses (Quarterly) | 3.814M |
| EPS Diluted (Quarterly) | -0.2213 |
| Gross Profit Margin (Quarterly) | -1.95K% |
| Profit Margin (Quarterly) | -14.57K% |
| Earnings Yield | -2.36K% |
| Normalized Earnings Yield | -2242.87 |